The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
EBITDA margins expand to 31.3%
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Subscribe To Our Newsletter & Stay Updated
